SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the National Oceanic and Atmospheric Administration deemed its consolidated deep-seabed mining application in substantial compliance, a critical regulatory step forward. The community views this as a major de-risking event, underscoring the strategic need for critical minerals for national security and the EV/AI revolution, with many anticipating significant future milestones.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a significant Q4 earnings and revenue beat, driven by accelerating Miplyffa sales that have ignited community optimism around the company's commercial transformation and potential European expansion. However, active discussions also highlight persistent concerns over management's long-term vision, historical stock performance, and the financial implications of a recent adverse legal ruling.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending sharply higher after reporting positive 12-month Phase 2 interim data for its bladder cancer candidate NDV-01, coupled with an oversubscribed $160 million private financing; the community is actively debating its strong momentum and future potential against concerns of dilution.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF is trending amidst heightened global tensions from the Middle East conflict pushing oil prices higher and recent weak jobs data. Community discussions are sharply split, with some anticipating a significant market downturn while others foresee a "short squeeze" and a broader recovery driven by hopes of de-escalation and economic support.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending due to recent strong earnings results that outperformed expectations, coupled with an optimistic fiscal year outlook and ongoing strategic expansion plans. The community is actively discussing the company's resilient "pizza and gas" business model and its valuation as it continues to grow within the convenience store sector.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

AGH is gaining significant attention following its announced merger with Powerus, a drone company backed by Eric Trump and Donald Trump Jr., marking a strategic shift into the defense drone sector. The community is debating the stock's potential for government contracts and a short squeeze, contrasting with concerns around past dilution and its previous business valuation.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is seeing an explosive rally and volume spike, driven by a recently announced $40 million private placement. This has ignited speculation of a short squeeze among bulls, though bears are quick to point out the offering's significantly lower per-share price, raising concerns about dilution and sustainability.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending following reports that President Trump declared the conflict with Iran "very complete" and "ahead of schedule," triggering a significant market rally and a sharp reversal in oil prices from recent highs. The community is intensely debating whether these comments are genuine peace signals or a strategic market manipulation, leaving many skeptical about the true resolution of the conflict and the market's future direction.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is experiencing extreme volatility as President Trump's comments about the Iran war being "very complete" and ships resuming passage through the Strait of Hormuz counter earlier concerns of escalating conflict and production cuts, which initially sent prices soaring. The community is deeply divided, with some actively shorting on hopes of de-escalation and strategic oil reserve releases, while others remain bullish, citing ongoing geopolitical risks and the critical importance of the Strait to global oil supply.

Vail Resorts, Inc. is a holding company, which engages in the operation of mountain resorts. It operates through the following segments: Mountain, Lodging, and Real Estate. The Mountain segment covers the operation of mountain resorts or ski areas, and related activities. The Lodging segment includes ownership of hotels, RockResorts, NPS concessionaire properties, condominium management, Colorado resort ground transportation operations, and mountain resort golf operations. The Real Estate segment owns, develops, and sells real estate in and around its resort communities. The company was founded by Pete Seibert and Earl Eaton in March 1957 and is headquartered in Broomfield, CO.

Vail Resorts Inc.

Vail Resorts is trending after significantly lowering its fiscal 2026 guidance, citing historically challenging weather conditions and low snowfall, which is amplifying community outcry regarding management's perceived operational failures, deteriorating guest experience, and the long-term sustainability of its business model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge

US stocks fell, Nasdaq down 1%, Dow down 1.71%, S&P 500 down 1.43%. Energy shares down 0.1%, consumer discretionary stocks down 2.8%. ZIM stock up after Q4 results. Autozi shares up 143%, Xenon...

Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $80.00

Needham & Company LLC lifted their price target on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a "buy" rating in a report on Monday...

Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year High - Time to Buy?

Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 52-Week High - Should You Buy...

Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.read more...

Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures

Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner, with FDA filing planned for 2026.read more...

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 6,053 call options on the company. This is an...

Needham & Company LLC Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

Needham & Company LLC boosted their price objective on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock a "buy" rating in a research report on Friday...

Wells Fargo & Company Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

Wells Fargo & Company increased their price objective on shares of Xenon Pharmaceuticals from $48.00 to $49.00 and gave the stock an "overweight" rating in a research report on Friday...

Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month High - What's Next?

Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 52-Week High - Time to Buy...

Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus

XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

XENE
Xenon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest XENE News

XENEXenon Pharmaceuticals Inc